Примери за използване на Fracture incidence на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Effect on fracture incidence.
Fracture Incidence in Postmenopausal Women.
Relative reduction in fracture incidence%.
Fracture incidence in postmenopausal women over 5 years.
Relative reduction in fracture incidence%(CI).
Table 2: Fracture incidence in postmenopausal women over 5 years.
Relative risk reduction in fracture incidence%(CI).
Table 2: Fracture incidence in p stmenopausal women over 5 years.
High milk intake is associated with higher mortality in both women and men,and with higher fracture incidence in women.
The effects of FABLYN on fracture incidence(table 2) were examined through 5 years; and BMD and.
Higher milk intake was associated with higher mortality in one cohort of women and in another cohort of men,with a higher fracture incidence in women.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator.
A diet higher in milk was associated with higher mortality in one cohort of women and in another cohort of men,and with higher fracture incidence in women.
Fracture incidence was evaluated as a safety endpoint but efficacy in fracture prevention cannot be estimated due to high number of discontinuations and open-label design.
The pivotal study was an 18-month double-blind, placebo-controlled, phase III study(TOP)of the effect of Preotact on fracture incidence in women with postmenopausal osteoporosis.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator.
The effects of alendronate on BMD and fracture incidence in post-menopausal women were studied in two initial efficacy studies of identical design(n=994), and in the Fracture Intervention Trial(FIT: n=6459).
The effects of FABLYN on fracture incidence(table 2) were examined through 5 years; and BMD and bone biomarkers in postmenopausal women with osteoporosis were examined through 3 years in the PEARL study.
The effects of alendronate on BMD and fracture incidence in post-menopausal women were studied in two initial efficacy studies of identical design(n=994), and in the Fracture Intervention Trial(FIT: n=6459).
Clinical efficacy Effect on fracture incidence The pivotal study was an 18-month double-blind, placebo-controlled, phase III study(TOP)of the effect of Preotact on fracture incidence in women with postmenopausal osteoporosis.
The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design(n=994) as well as in the Fracture Intervention Trial(FIT: n=6,459).
Incidence of clinical vertebral fracture.
In particular there was no clear evidence of efficacy on incidence of fracture or on pain.
In particular there was no clear evidence of efficacy on incidence of fracture or on pain.
The reduction in the incidence of vertebral fracture was similar among bazedoxifene and raloxifene treatment groups.
Table 4 Between treatment comparisons of the incidence of key clinical fracture variables.
The incidence of hip fracture was 1.2% in the placebo group compared to 0.7% in the Prolia group at 3 years.
Table 3 Between treatment comparisons of the incidence of key clinical fracture variables over 3 years.
Incidence of patients with vertebral fracture and relative risk reduction Placebo.